Inogen Inc (INGN) - Net Assets
Based on the latest financial reports, Inogen Inc (INGN) has net assets worth $197.18 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($307.01 Million) and total liabilities ($109.83 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check INGN financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $197.18 Million |
| % of Total Assets | 64.22% |
| Annual Growth Rate | 27.28% |
| 5-Year Change | -50.27% |
| 10-Year Change | 29.73% |
| Growth Volatility | 78.89 |
Inogen Inc - Net Assets Trend (2011–2024)
This chart illustrates how Inogen Inc's net assets have evolved over time, based on quarterly financial data. Also explore Inogen Inc assets under control for the complete picture of this company's asset base.
Annual Net Assets for Inogen Inc (2011–2024)
The table below shows the annual net assets of Inogen Inc from 2011 to 2024. For live valuation and market cap data, see how much is Inogen Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $173.86 Million | -15.11% |
| 2023-12-31 | $204.81 Million | -31.13% |
| 2022-12-31 | $297.41 Million | -19.67% |
| 2021-12-31 | $370.23 Million | +5.89% |
| 2020-12-31 | $349.62 Million | +1.45% |
| 2019-12-31 | $344.62 Million | +11.02% |
| 2018-12-31 | $310.42 Million | +36.73% |
| 2017-12-31 | $227.04 Million | +24.69% |
| 2016-12-31 | $182.09 Million | +35.87% |
| 2015-12-31 | $134.02 Million | +13.43% |
| 2014-12-31 | $118.15 Million | +109.86% |
| 2013-12-31 | $56.30 Million | +97.02% |
| 2012-12-31 | $28.57 Million | +278.18% |
| 2011-12-31 | $7.56 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Inogen Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7702300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $24.00K | 0.01% |
| Other Comprehensive Income | $-1.50 Million | -0.86% |
| Other Components | $328.17 Million | 188.76% |
| Total Equity | $173.86 Million | 100.00% |
Inogen Inc Competitors by Market Cap
The table below lists competitors of Inogen Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ABL Group ASA
OL:ABL
|
$156.41 Million |
|
China Harmony Auto Holding Limited
F:HA5
|
$156.43 Million |
|
Havilah Resources Ltd
AU:HAV
|
$156.51 Million |
|
JADESTONE ENERGY LS -001
F:8KW
|
$156.53 Million |
|
Coastal Contracts Bhd
KLSE:5071
|
$156.35 Million |
|
LaFayette Acquisition Corp. Ordinary Share
NASDAQ:LAFA
|
$156.35 Million |
|
E-Life Mall Corp
TW:6281
|
$156.22 Million |
|
Punjab Chemicals & Crop Protection Limited
NSE:PUNJABCHEM
|
$156.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Inogen Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 204,812,000 to 173,860,000, a change of -30,952,000 (-15.1%).
- Net loss of 35,888,000 reduced equity.
- Share repurchases of 546,000 reduced equity.
- Other comprehensive income decreased equity by 2,726,000.
- Other factors increased equity by 8,208,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-35.89 Million | -20.64% |
| Share Repurchases | $546.00K | -0.31% |
| Other Comprehensive Income | $-2.73 Million | -1.57% |
| Other Changes | $8.21 Million | +4.72% |
| Total Change | $- | -15.11% |
Book Value vs Market Value Analysis
This analysis compares Inogen Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.95x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 15.10x to 0.95x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $0.46 | $6.98 | x |
| 2012-12-31 | $1.75 | $6.98 | x |
| 2013-12-31 | $3.12 | $6.98 | x |
| 2014-12-31 | $6.55 | $6.98 | x |
| 2015-12-31 | $6.47 | $6.98 | x |
| 2016-12-31 | $8.63 | $6.98 | x |
| 2017-12-31 | $10.37 | $6.98 | x |
| 2018-12-31 | $13.79 | $6.98 | x |
| 2019-12-31 | $15.49 | $6.98 | x |
| 2020-12-31 | $15.91 | $6.98 | x |
| 2021-12-31 | $16.46 | $6.98 | x |
| 2022-12-31 | $13.01 | $6.98 | x |
| 2023-12-31 | $8.84 | $6.98 | x |
| 2024-12-31 | $7.35 | $6.98 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Inogen Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -20.64%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -10.69%
- • Asset Turnover: 1.13x
- • Equity Multiplier: 1.70x
- Recent ROE (-20.64%) is below the historical average (-1.70%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -26.50% | -6.54% | 1.27x | 3.19x | $-2.76 Million |
| 2012 | 1.97% | 1.16% | 1.02x | 1.67x | $-2.29 Million |
| 2013 | 45.18% | 33.71% | 0.92x | 1.46x | $19.81 Million |
| 2014 | 5.78% | 6.07% | 0.80x | 1.19x | $-4.99 Million |
| 2015 | 8.64% | 7.29% | 0.99x | 1.20x | $-1.82 Million |
| 2016 | 11.27% | 10.12% | 0.95x | 1.18x | $2.31 Million |
| 2017 | 9.25% | 8.42% | 0.91x | 1.21x | $-1.70 Million |
| 2018 | 16.70% | 14.48% | 0.95x | 1.21x | $20.80 Million |
| 2019 | 6.08% | 5.79% | 0.81x | 1.30x | $-13.51 Million |
| 2020 | -1.67% | -1.89% | 0.67x | 1.32x | $-40.79 Million |
| 2021 | -1.71% | -1.77% | 0.73x | 1.32x | $-43.36 Million |
| 2022 | -28.17% | -22.21% | 0.93x | 1.36x | $-113.51 Million |
| 2023 | -50.02% | -32.46% | 0.97x | 1.59x | $-122.93 Million |
| 2024 | -20.64% | -10.69% | 1.13x | 1.70x | $-53.27 Million |
Industry Comparison
This section compares Inogen Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,432,799,891
- Average return on equity (ROE) among peers: -74.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Inogen Inc (INGN) | $197.18 Million | -26.50% | 0.56x | $156.38 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About Inogen Inc
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One and Inogen Rove, an ambulatory solutions for long-term ox… Read more